HIV-1 Infection in Children: Current Practice and Future Predictions

  • Lauri-Ann Van der Poel
  • Saul N. Faust
  • Gareth Tudor-Williams
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 549)

Abstract

This review will discuss the global epidemiology and clinical classification of HIV-1 in children, and the management and treatment principles in an industrialized economic setting. The epidemiology highlights the burden of disease that the global epidemic is placing on less-developed countries. Extending the benefits of advances in treatment to children and families in high prevalence regions is a priority and a challenge for health care systems and governments internationally.

Keywords

Hepatitis Lymphoma Pneumonia Sarcoma Cardiomyopathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blanche, S., Newell, M.L., Mayaux, M.L., Dunn, D.T., Teglas, J.P., Rouzioux, C., and Peckham, C.S. (1997). Morbidity and mortality in European children vertically infected by HIV-1. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14, 442–450.PubMedCrossRefGoogle Scholar
  2. Cassol, S., Butcher, A., Kinard, S., Spadoro, J., Sy, T., Lapointe, N. et al. (1994). Rapid screening for early detection of mother-to-child transmission of HIV-1. J. Clin. Microbiol. 32, 2641–2645.PubMedGoogle Scholar
  3. Centers for Disease Control. (1994). 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 43(RR-12), 1–10.Google Scholar
  4. Childrens HIV Association of the UK and Ireland website, [www.bhiva.org/chiva]
  5. De Rossi, A., Walker, A.S., Klein, N., De Forni, D., King, D., and Gibb, D.M. for PENTA (2002). Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J. Infect. Dis. 186, 312–320.PubMedCrossRefGoogle Scholar
  6. Dunn, D. and HIV Paediatric Prognostic Markers Collaborative Study group. (2003). Short term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362(9396), 1595–1596.CrossRefGoogle Scholar
  7. Gibb, D.M., Duong, T., Tookey, P.A., Sharland, M., Tudor-Williams, G., Noveli, V. et al., On behalf of the National Study of HIV in Pregnancy and Childhood (NSHPC) and the Collaborative HIV Paediatric Study (CHIPS). (2003). Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ, 327(7422), 1019.Google Scholar
  8. Gibb, D.M., Masters, J., Shingadia, D., Trickett, S., Klein, N., Duggan, C. et al. (1997). A family clinic—optimising care for HIV infected children and their families. Arch. Dis. Child 77, 478–482.PubMedCrossRefGoogle Scholar
  9. Gulick R.M., Ribaudo H.J., Shikuma C.M. et al. (2003). ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France 13-16 July [Abstract Oral 41].Google Scholar
  10. Lyles, R.H., Munoz, A., Yamashita, T.E., Bazmi H., Detels, R., Rinaldo, C.R. et al. (2000). Natural history of HIV-1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J. Infect. Dis. 18, 872–880.CrossRefGoogle Scholar
  11. Paediatric European Network for Treatment of AIDS (PENTA). (2002). Comparison of dual nucleoside-analogue reverse transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: The PENTA 5 randomized trial. Lancet 359, 733–740.CrossRefGoogle Scholar
  12. Rosenberg, E.S., Altfeld, M., Poon, S.H., Phillips, M.N., Wilkes, B.M., Eldridge, R.L. et al. (2000). Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523–526.PubMedCrossRefGoogle Scholar
  13. Sharland, M., di Zub, G.C., Ramos, J.T., Blanche, S., Gibb, D.M., and PENTA Steering Committee. (2002). PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. HIV Med 3, 215–226 [www.pentatrials.org].PubMedCrossRefGoogle Scholar
  14. Shearer, W.T., Quinn, T.C., LaRussa, P., Lew, J.F., Mofenson, L., Almy, S. et al. (1997). Viral load and disease progression in infants infected with HIV-1. N. Engl. J. Med. 336, 1337–1342.PubMedCrossRefGoogle Scholar
  15. Shingadia, D., Viani, R.M., Yogev, R., Binns, H., Dankner, W.M., Spector, S.A., and Chadwick, E.G. (2000). Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics 105, E80.PubMedCrossRefGoogle Scholar
  16. Squires K.E., Thiry A., Giordano et al. (2002). Atazanavir QD vs efavirenz 3 QD with fixed dose ZDV +3TC BID comparison of antiviral efficacy and safety. Week 48 results from BMS A1424-034 phase III pivotal study. XXXXII ICAAC., Chicago.Google Scholar
  17. Staszewski, S., Morales-Ramirez, J., Tashima, K.T., Rachlis, A., Skiest, D., Stanford, J. et al. (1999). Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 341, 1865–1873.PubMedCrossRefGoogle Scholar
  18. Taha, T.E., Graham, S.M., Kumwenda, N.I., Broadhead, R.L., Hoover, D.R., Markakis, D. et al. (2000). Morbidity among HIV-1 infected and uninfected African children. Pediatrics 106, E77.PubMedCrossRefGoogle Scholar
  19. The European Collaborative Study. (1992). Age-related standards for T lymphocyte subsets based on uninfected children born to HIV-1 infected women. Pediatr. Infect. Dis. J. 11, 1018–1026.CrossRefGoogle Scholar
  20. United Nations Programme on HIV/AIDS (UNAIDS). website: http://www.unaids.org
  21. Verweel, G., Sharland, M., Lyall, H., Novelli, V., Gibb, D.M., Dumont, G. et al. (2003). Nevirapine use in HIV-1 children. AIDS 17, 1639–1647.PubMedCrossRefGoogle Scholar

Copyright information

© Science+Business Media New York 2004

Authors and Affiliations

  • Lauri-Ann Van der Poel
  • Saul N. Faust
  • Gareth Tudor-Williams

There are no affiliations available

Personalised recommendations